In focus · trending topic

microbiome preserving

1 stories · following the connections

Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI

By Nasdaq OMXSep 5, 2017, 11:01 AM UTC